FIELD: medicine.
SUBSTANCE: group of inventions discloses a solid pharmaceutical composition for the treatment of a disease associated with orexin, wherein the said solid pharmaceutical composition contains an active ingredient, wherein the said active ingredient is a compound of formula (II) or a pharmaceutically acceptable salt thereof or a mixture thereof; and the D90 particle size of the active ingredient is 35 μm or less. The group of inventions also discloses a method of production of a tablet, a dosage form for treating an orexin-related disease and a method of treating an orexin-related disease.
EFFECT: ensuring good stability, good solubility and high bioavailability of a solid pharmaceutical composition containing a compound of formula (II).
20 cl, 10 dwg, 10 tbl, 21 ex
Title | Year | Author | Number |
---|---|---|---|
TABLET AND METHOD OF ITS PREPARATION | 2019 |
|
RU2796301C2 |
TABLET AND METHOD FOR PRODUCTION THEREOF | 2016 |
|
RU2697660C2 |
MEDICAL USE OF PYRROLOPYRIMIDINE COMPOUND AND SOLID PHARMACEUTICAL COMPOSITION OF PYRROLOPYRIMIDINE COMPOUND | 2019 |
|
RU2810112C2 |
SOLID PHARMACEUTICAL COMPOSITION CONTAINING TLR7 AGONIST | 2020 |
|
RU2822480C2 |
PHARMACEUTICAL PREPARATION | 2019 |
|
RU2756452C1 |
PHARMACEUTICAL COMPOSITION COMPRISING FIMASARTAN AND HYDROCHLOROTHIAZIDE | 2013 |
|
RU2613900C2 |
PHARMACEUTICAL COMBINED DRUG | 2014 |
|
RU2639818C2 |
COMPOSITE FORMULATION FOR ORAL ADMINISTRATION COMPRISING EZETIMIBE AND ROSUVASTATIN | 2014 |
|
RU2683937C2 |
NEW COMPOSITION OF LAPATINIB AS A SOLID DOSAGE FORM FOR ORAL USE AND A METHOD OF ITS MANUFACTURE | 2019 |
|
RU2821950C2 |
PHARMACEUTICAL COMPLEX COMPOSITION CONTAINING AMLODIPINE, LOSARTAN AND ROSUVASTATIN | 2016 |
|
RU2724338C2 |
Authors
Dates
2023-12-15—Published
2021-04-14—Filed